Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Recommendation of “Buy” by Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned an average recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have covered the stock in the last year is $25.83.

Several research firms recently issued reports on CNTA. BMO Capital Markets upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Jefferies Financial Group upped their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. B. Riley assumed coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target for the company. Finally, Guggenheim upped their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $17.01 on Friday. Centessa Pharmaceuticals has a 12-month low of $6.65 and a 12-month high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -11.12 and a beta of 1.52. The firm’s fifty day moving average price is $16.87 and its 200 day moving average price is $14.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 77,705 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $16.39, for a total value of $1,273,584.95. Following the sale, the general counsel now owns 125,785 shares in the company, valued at approximately $2,061,616.15. This trade represents a 38.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $15.38, for a total value of $180,591.96. Following the sale, the insider now directly owns 183,266 shares in the company, valued at approximately $2,818,631.08. This trade represents a 6.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 368,023 shares of company stock valued at $6,335,574. Insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC raised its stake in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. Atria Investments Inc raised its stake in shares of Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares in the last quarter. Quarry LP lifted its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after buying an additional 6,785 shares in the last quarter. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.